Answers are grounded in this paper and cite their sources.
Background: Cholangiopathies, such as primary sclerosing cholangitis (PSC) involve bile acid toxicity, epithelial injury, and innate immune activation. While FXR regulates bile acid homeostasis, it remains unknown whether different FXR agonists elicit distinct protective responses. To determine whether early FXR activation can prevent the development of lithocholic acid (LCA)-induced cholestatic injury, we administered FXR agonists during LCA exposure and evaluated their effects on hepatocyte, immune, and endocrine responses. Methods: Adult male C57BL/6 mice were fed a 1%; LCA diet for 2 days and treated by intravenous infusion with FXR agonists GW4064 (30 mg/kg/day) or obeticholic acid (OCA; 20 mg/kg/day) for 4 days, initiated 2 days before LCA exposure. Liver injury was assessed by serum biochemistry, histology, immunostaining, intrahepatic mononuclear cell profiling, ChIP assay, and bulk liver RNA sequencing. Huh7 and T84 cells were used for co-culture. Results: LCA induced marked cholestatic injury with elevated liver enzymes, bile duct injury, macrophage and neutrophil infiltration, and activation of inflammatory, oxidative stress, apoptotic, and MYC-dependent transcriptional programs. FXR agonists prevented biochemical and histologic injury, restored hepatocyte bile acid transport and feedback regulation, reduced oxidative stress and apoptosis, and attenuated coordinated macrophage–neutrophil activation. Transcriptomic analyses revealed agonist-dependent effects, with GW4064 and OCA suppressing LCA-induced injury pathways. FXR activation induced ileal FXR targets and Fgf15, reduced intestinal macrophage infiltration, and activated hepatic STAT5 signaling. Direct FGF19 treatment of Huh7 cells recapitulated hepatocyte protective effects and STAT5 activation. Conclusions: FXR agonist treatment mitigates LCA-induced cholestatic liver injury by restoring hepatocyte bile acid homeostasis, suppressing innate immune inflammation, and engaging an ileal FXR–FGF15/19–hepatic STAT5 survival axis, with distinct agonist-dependent transcriptional outcomes.
No takes yet. Share an insight, caveat, or question.
Ghosh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: